US 11,718,612 B2
Inhibitors of receptor interacting protein kinase I for the treatment of disease
Richard T. Lewis, Missouri City, TX (US); Matthew Hamilton, Missouri City, TX (US); William J. Ray, Houston, TX (US); Fernando Alvarez, Austin, TX (US); Naphtali Reyna, Arlington, TX (US); Jason Cross, Pearland, TX (US); and Suyambu Kesava Vijayan Ramaswamy, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Sep. 8, 2020, as Appl. No. 17/14,184.
Claims priority of provisional application 62/896,786, filed on Sep. 6, 2019.
Prior Publication US 2021/0094951 A1, Apr. 1, 2021
Int. Cl. C07D 487/04 (2006.01); C07D 471/04 (2006.01); A61K 31/4035 (2006.01); A61K 31/407 (2006.01); A61K 31/415 (2006.01); A61K 31/4172 (2006.01); A61K 31/4196 (2006.01); A61K 31/4245 (2006.01); A61K 31/437 (2006.01); A61K 31/497 (2006.01); A61K 31/4985 (2006.01); A61K 31/5383 (2006.01); A61K 31/551 (2006.01); A61K 45/06 (2006.01); C07D 209/44 (2006.01); C07D 231/44 (2006.01); C07D 233/90 (2006.01); C07D 249/14 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 498/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/407 (2013.01); A61K 31/4035 (2013.01); A61K 31/415 (2013.01); A61K 31/4172 (2013.01); A61K 31/4196 (2013.01); A61K 31/4245 (2013.01); A61K 31/437 (2013.01); A61K 31/497 (2013.01); A61K 31/4985 (2013.01); A61K 31/5383 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); C07D 209/44 (2013.01); C07D 231/44 (2013.01); C07D 233/90 (2013.01); C07D 249/14 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01)] 10 Claims
 
1. A compound of structural Formula I

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
Y2 is CR2;
Y3 a bond;
Y4 CR4;
Y5 is N;
Y6 is N;
R1a is phenyl, which is optionally substituted with one or more R7;
R1b and R2, together with the intervening atoms, combine to form
an unsubstituted 6-membered heterocycloalkyl;
R3 is chosen from hydrogen and alkyl;
R4 is chosen from hydrogen and halo;
R5 hydrogen;
R5b is chosen from phenyl and pyridyl, either of which is optionally substituted with one or more R10;
each R7 is independently chosen from halo, cyano, hydroxy, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, aminoalkyl, acylaminoalkyl, (haloalkyl)aminoalkyl, alkylsulfonylaminoalkyl, arylalkyl, heteroarylalkyl, haloalkoxy, heteroaryl optionally substituted with alkyl, and heterocycloalkyl optionally substituted with alkyl, or
two or more R7, together with the intervening atoms, can form a heterocycloalkyl or heteroaryl;
and
each R10 is independently chosen from alkyl, haloalkyl, amino, aminoalkyl, aminocarbonyl, alkoxy, haloalkoxy, cyano, halo, and hydroxy.